In 2024, Sumitomo Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Sumitomo Pharma has also provided a category-level breakdown for 11 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy/Paste is a PRO feature. | Copy/Paste is a PRO feature. | 0000000 |
Total Scope 2 | ||||
Market-Based | Copy/Paste is a PRO feature. | 0000000 | Copy/Paste is a PRO feature. | 0000000 |
Location-Based | Copy/Paste is a PRO feature. | 0000000 | Copy/Paste is a PRO feature. | 0000000 |
Total Scope 3 | Copy/Paste is a PRO feature. | Copy/Paste is a PRO feature. | 0000000 | 0000000 |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 0000000 | Copy/Paste is a PRO feature. | Copy/Paste is a PRO feature. | 0000000 |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Sumitomo Pharma’s data sources below and access millions more through our Disclosure Search.
In 2024, the total operational greenhouse gas (GHG) emissions of Sumitomo Pharma amounted to 61,239 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2023, the total operational greenhouse gas (GHG) emissions of Sumitomo Pharma decreased by 13.11%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2024, the total Scope 1 emissions of Sumitomo Pharma were 23,101 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, Sumitomo Pharma's Scope 1 emissions have increased by 20.19%, reflecting a rising long-term trend in Scope 1 emissions over time.ab
Compared to the previous year (2023), Sumitomo Pharma's Scope 1 emissions decreased by 14.73%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2024, Sumitomo Pharma reported Scope 2 greenhouse gas (GHG) emissions of 23,157 tCO₂e using the market-based method and 38,138 tCO₂e using the location-based method.a
Compared to the previous year (2023), Sumitomo Pharma's Scope 2 emissions (Location-Based) fell by 12.1% in 2024, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.a
In 2024, Sumitomo Pharma reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2024, Sumitomo Pharma reported 268,271 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2024 disclosure of Sumitomo Pharma includes a breakdown across 11 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2024, Sumitomo Pharma reported total Scope 3 emissions of 268,271 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 98.53% of these emissions originated from upstream activities such as purchased goods and capital goods, while 1.47% came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2023), Sumitomo Pharma's Scope 3 emissions decreased by 24.58%, highlighting the company's efforts to lower indirect emissions from its value chain.a
In 2024, Sumitomo Pharma reported emissions for 11 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This reflects a high level of granularity and transparency in the company's emissions reporting.
In 2024, the largest contributors to Sumitomo Pharma's Scope 3 emissions were:a
In 2024, Sumitomo Pharma reported Scope 1 greenhouse gas (GHG) emissions of 23,101 tCO₂e and total revenues of USD 2,077 millions. This translates into an emissions intensity of 11.12 tCO₂e per millions USD.a
In 2024, Sumitomo Pharma reported a Scope 1 emissions intensity of 11.12 tCO₂e per millions USD. Compared to the peer group median of 4.47, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a
In 2024, Sumitomo Pharma ranked 19 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Sumitomo Pharma among the least efficient performers, with one of the highest emissions intensities in its sector.a
In 2024, Sumitomo Pharma reported a total carbon footprint of 329,510 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 22.68% decrease compared to 2023, indicating progress in reducing its overall greenhouse gas output.a
The largest contributor to Sumitomo Pharma's total carbon footprint was Scope 3 emissions, accounting for 81.42% of the company's total carbon footprint, followed by Scope 2 emissions at 11.57%.a